The Food and Drug Administration is reporting shortages of GE Healthcare’s iohexol and iodixanol intraveneous contrast media products for computed tomography imaging.  

In an April 19 letter to customers, GE Healthcare said it was rationing orders for its iohexol products after a COVID-19 lockdown temporarily shut down its production facility for iodinated contrast media in Shanghai, China. 

Nancy Foster, AHA’s vice president for quality and patient safety policy, said, “We are aware of this global shortage of IV contrast fluid due to production shutdowns in China and have raised this issue with the Administration. While we have been told to expect normal production to resume late next month, hospitals are exploring various conservation strategies including the use of other imaging technologies, using other contrast agents, rationing contrast and ensuring every available drop of contrast dye is used efficiently, and postponing some scans that can be postponed, to give a few examples, in order to continue to provide needed care. The AHA will continue to monitor this situation and provide updates to the hospital and health system field.”

Related News Articles

Headline
President Biden yesterday invoked the Defense Production Act to ensure manufacturers have the necessary ingredients to make infant formula in the United States…
Headline
The House Energy and Commerce Health Subcommittee today passed, as amended, the Restoring Hope for Mental Health and Well-being Act (H.R. 7666),…
Headline
In a letter today, AHA asked GE Healthcare to provide additional information to help member hospitals manage the current shortage of GE intraveneous…
Headline
The House Energy and Commerce Health Subcommittee yesterday voted unanimously to advance to the full committee the Restoring Hope for Mental Health and Well-…
News
The Food and Drug Administration today recommended strategies for health care providers to conserve prefilled 0.9% sodium chloride intravenous lock/flush…
News
To help prevent medical product shortages and ensure access to essential drugs and devices, the Food and Drug Administration should make information on medical…